THE E ROLE LE AND R RESP SPONSI SIBILITY O OF THE PHARMACEUTI - PowerPoint PPT Presentation

THE E ROLE LE AND R RESP SPONSI SIBILITY O OF THE PHARMACEUTI TICAL I INDUSTR TRY I IN THE PREVEN ENTION, , TREATM TMENT T AND C D CURE OF OF PUBLIC H HEALTH P PRIOR ORITY DISEASES ES G GLOBALL LLY Stefan Oschmann, IFPMA President Chairman of the Executive Board & CEO, Merck KGaA, Darmstadt, Germany Boston, September 15, 2016 Merck KGaA Darm stadt, Germ any

IFPMA A trusted partner in global health At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere. We collaborate with: Decision Health Patient NGOS Business Makers Professionals Groups and Coalitions 3 Role of Pharm a I ndustry l September 2016

Global health – a changing landscape Key changes and em erging trends are setting the scene Key changes Description • Rise of NCDs Health transition: Epidem iologic and • Ageing populations • Injuries dem ographic changes • Large youth population in developing countries • Concern over new pandemics and epidemics Outbreaks and global threats • Antimicrobial resistance • Effects of climate change on health Environm ental threats • Environmental degradation • Transition of LICs to MICs Econom ic developm ents • Increased importance of domestic financing • Catastrophic health expenses Political developm ents • Rise of large MICs as regional and global powers 4 Role of Pharm a I ndustry l September 2016

Pharmaceutical industry engagement From philanthropy to partnerships 3 Partnerships 2 Philanthropy  Gavi Alliance (2000)  The Global Fund (2002) 1 Traditional aid  Mectizan Donation  Gates CEO Roundtable on Program (1987) NTDs (2012)  Bill & Melinda Gates  Global Financing Facility for  Mainly government-led Foundation (1999) reproductive, maternal, health and aid initiatives newborn, child &  Few NGOs (e.g. Médecins adolescent health (2015) Sans Frontières, founded  AMR declaration (2016) in 1971)  Today: over 300 health partnerships implemented by the pharmaceutical industry 5 Role of Pharm a I ndustry l September 2016

Neglected Tropical Diseases (NTDs) London Declaration: an unprecedented collaborative effort • 1.7 billion people affected • 3 billion people are at risk • 500,000 people will die annually Uniting to Com bat NTDs, Reaching the Unreached, 4 t h Progress Report of the London Declaration Uniting to Com bat NTDs, Reaching the Unreached, 4 t h Progress Report of the London Declaration 6 Role of Pharm a I ndustry l September 2016

Neglected Tropical Diseases (NTDs) Countries Significant progress has already been achieved 2.4 bi billion t tabl ablets do donated i in 2015 1.5 million on treatmen ents 11.7% i increase from 2014 014 Uniting to Com bat NTDs, Reaching the Unreached, 7 Role of Pharm a I ndustry l September 2016 4 t h Progress Report of the London Declaration

Neglected Tropical Diseases (NTDs) I ncreasing treatm ent coverage ( four exam ples) 100 50.2 % 83 % 84 % million tablets Schistosom iasis Lym phatic filariasis ( LF) Visceral leishm aniasis Guinea w orm disease There has been a great LF showed the greatest The global Guinea worm The percentage of patients progress in the past year. increase of all diseases treated with AmBisome in eradication program has Drug donations reached treated by MDA in 2014 Asia increased to 84% in made extraordinary 100 million tablets in 2015, (40.7% to 50.2% ) and 2015 – a significant leap progress. The number of provided by Merck KGaA, reached the largest number from the treatment rate of human cases was reduced Darmstadt, Germany. of people globally. by 83% (22 vs. 126 in 10% in 2010. 2014). 8 Role of Pharm a I ndustry l September 2016 Uniting to Com bat NTDs, Reaching the Unreached, 4 t h Progress Report of the London Declaration

Neglected Tropical Diseases (NTDs) Our contribution: elim inating schistosom iasis Nearly 260 million people in Africa suffer from the tropical disease schistosom iasis, resulting in 200,000 deaths a year. In children, the parasitic worm disease stunts growth and reduces their ability to learn. Together with W HO, we have taken up the fight against this condition. Thanks to our praziquantel tablets, 7 4 m illion patients have already received treatment – most of them children. And we intend to continue the fight – until schistosom iasis has been elim inated in Africa. 9 Role of Pharm a I ndustry l September 2016

Antimicrobial Resistance (AMR) A serious public health threat Joint I ndustry Declaration on Com bating Antim icrobial Resistance ( January 2 0 1 6 ) Call to action signed by: AMR in 2 0 5 0 • 85 companies: pharmaceutical, generics, diagnostics & biotechnology companies 10,000,000 • 9 industry associations Signatories com m it to: • Reducing the development of drug resistance • Increasing investment in R&D that meets global public health needs AMR in 2 0 1 4 • Improve access to high-quality antibiotics for all 700,000 WHO, AMR fact sheet # 194, April 2015 10 Role of Pharm a I ndustry l September 2016 I FPMA, Rethinking the Way We Fight Bacteria

Non-Communicable Diseases (NCDs) Tackling a grow ing global burden W HO NCD Voluntary Global Targets Medicines in Developm ent ( selected categories, 2 0 1 5 ) • 25% reduction in the overall mortality from CVD, cancer, diabetes, or chronic respiratory diseases • 25% reduction in the prevalence of raised blood pressure • Halt the rise of diabetes and obesity • At least 50% of eligible people receive drug therapy and counselling to prevent heart attacks and strokes • 80% availability of basic technologies and essential medicines required to treat major NCDs (9 goals overall, all changes against baseline, text shortened for display reasons) I FPMA, The Pharmaceutical I ndustry and Global Health, 2015 11 Role of Pharm a I ndustry l September 2016

Innovative approaches Addressing access challenges holistically 12 Role of Pharm a I ndustry l September 2016

Industry commitment Sustainable and transform ational health partnerships Build stronger health Pioneer innovative tools Improve scientific Help economies grow by systems, improve and approaches knowledge in improving health in healthcare access, health low- and middle-income developing countries awareness, and training countries and discover new medicines and vaccines I FPMA Developing World Health Partnerships Directory 13 Role of Pharm a I ndustry l September 2016

Tackling global health challenges The industry is ready to w ork w ith stakeholders from all sectors States and Global health Non-state international partnerships actors organizations  Multilateral and  UNITAID  Philanthropic regional organizations  Gavi development banks  Professional  Global Fund  WHO organizations  Other global health  Regional  Global civil partnerships organizations society and non- governmental  National organizations governments  Private industry  UN agencies  Academic  Clubs: G7, G20 institutions Chatham House, “Rethinking the Global Health System,” September 2015 14 Role of Pharm a I ndustry l September 2016

Universal Health Coverage (UHC) The industry has proposed eight guiding principles I ndustry w orking collaboratively to support countries to achieve the UHC target 1 . Equitable Access: Roche Scientific Partnership for HER2 Testing Excellence 2 . Efficiency: 4 Healthy Habits 3 . Quality: Global Pharma Health Fund (GPHF) 4 . I nclusiveness: Boehringer Ingelheim – Making More Health 5 . Availability: Pfizer International Trachoma Initiative (ITI) 6 . Adaptability: Sanofi Next Billion Patients in Egypt 7 . Choice: Astra Zeneca Young Health Program 8 . I nnovation: Global Health Innovation Technology Fund (GHIT) I FPMA, I nnovative Biopharm aceutical I ndustry Perspectives on UHC, 15 Role of Pharm a I ndustry l September 2016 Proposed public Policy Perspectives I FPMA, Translating Principles into Practice

Outlook Concerted action is the key to achieving Universal Health Coverage ( UHC) Everyone has a seat at the table Establish common ground and agree on roles & responsibilities Communicate continuously to establish trust and governance principles emphasizing transparency and accountability Build on existing learnings Stepwise approach to tackling challenges Work together on improving the predictability of markets and their enabling environment for optimum outcomes Invest in robust monitoring and evaluation capabilities to inform sustainability planning 16 Role of Pharm a I ndustry l September 2016